Last reviewed · How we verify
NCT04865445
Drug-drug Interaction Study of Midazolam and AT-527 (R07496998)
Phase 1 trial testing AT-527 550 mg + midazolam in Healthy Volunteer Study in 24 participants. Completed in 15 May 2021.
15 May 2021
Quick facts
| Lead sponsor | Atea Pharmaceuticals, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 22 April 2021 |
| Primary completion | 15 May 2021 |
| Estimated completion | 15 May 2021 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- AT-527 550 mg + midazolam — full drug profile →
- AT-527 550 mg + midazolam — full drug profile →
Conditions studied
- Healthy Volunteer Study — all drugs for Healthy Volunteer Study →
Sponsor
Atea Pharmaceuticals, Inc. — full company profile →
Who can join
Adults 18 to 65, any sex, with Healthy Volunteer Study. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Drug-drug interaction study of midazolam and AT-527 (R07496998)
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug-Metabolizing Enzymes.
Zhou XJ, Vo A, Morelli G, Montrond M, et al · · 2026 · PMID 42053458 · DOI 10.1002/jcph.70170
Verify or expand the search:
- PubMed search for NCT04865445
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy Volunteer Study
Currently open trials in the same condition.
- NCT06825364 — Near-InfraRed Spectroscopy of Auricular Stimulation · NA · recruiting
- NCT07021079 — Muscle Vibration as a Countermeasure Against Hypoactivity-induced · NA · recruiting
- NCT06945614 — Exploratory Clinical Study to Assess Safety and Efficacy of Xenon Gas Inhalation to Control Neuroinflammation · Phase 1 · recruiting
Other Atea Pharmaceuticals, Inc. trials
Trials by the same sponsor.
- NCT07272889 — Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG) · Phase 1 · completed
- NCT07007806 — Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir · Phase 1 · completed
- NCT06921941 — Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin · Phase 1 · completed
- NCT06356194 — Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir · Phase 1 · completed
- NCT06204679 — Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04865445 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Atea Pharmaceuticals, Inc.
- Last refreshed: 29 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04865445.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing